A high throughput scintillation proximity imaging assay for protein methyltransferases Journal Article


Authors: Ibáñez, G.; Shum, D.; Blum, G.; Bhinder, B.; Radu, C.; Antczak, C.; Luo, M.; Djaballah, H.
Article Title: A high throughput scintillation proximity imaging assay for protein methyltransferases
Abstract: Protein methyltransferases (PMTs) orchestrate epigenetic modifications through post-translational methylation of various protein substrates including histones. Since dysregulation of this process is widely implicated in many cancers, it is of pertinent interest to screen inhibitors of PMTs, as they offer novel target-based opportunities to discover small molecules with potential chemotherapeutic use. We have thus developed an enzymatic screening strategy, which can be adapted to scintillation proximity imaging assay (SPIA) format, to identify these inhibitors. We took advantage of S-adenosyl-L-[3H-methyl]- methionine availability and monitored the enzymatically catalyzed [3H]-methyl addition on lysine residues of biotinylated peptide substrates. The radiolabeled peptides were subsequently captured by streptavidin coated SPA imaging PS beads. We applied this strategy to four PMTs: SET7/9, SET8, SETD2, and EuHMTase1, and optimized assay conditions to achieve Z' values ranging from 0.48 to 0.91. The robust performance of this SPIA for the four PMTs was validated in a pilot screen of approximately 7,000 compounds. We identified 80 cumulative hits across the four targets. NF279, a suramin analogue, was found to specifically inhibit SET7/9 and SETD2 with IC50 values of 1.9 and 1.1 μM, respectively. Another identified compound, Merbromin, a topical antiseptic, was classified as a pan-active inhibitor of the four PMTs. These findings demonstrate that our proposed SPIA strategy is generic for multiple PMTs and can be successfully implemented to identify novel and specific inhibitors of PMTs. The specific PMT inhibitors may constitute a new class of anti-proliferative agents for potential therapeutic use. © 2012 Bentham Science Publishers.
Keywords: signal transduction; unclassified drug; methylation; cisplatin; enzyme inhibition; protein targeting; drug discovery; enzyme inhibitor; high-throughput screening assays; inhibitor; enzyme inhibitors; histone-lysine n-methyltransferase; catalysis; streptavidin; suramin; biotinylation; biotin; dopa; protein methyltransferases; acid; set7/9; protein methyltransferase; s adenosylmethionine; process optimization; cyproheptadine; acriflavine; merbromin; set8; scintillation counting; 2',2' bisepigallocatechin monogallate; epitheaflavin monogallate; euhmtase1; red shifted imaging beads; setd2; spa technology; 2',2' bisepigallocatechin digallate; 6 hydroxy dl dopa; acetriazoic acid; alexidine; aurintricarboxylic acid; cadmium acetate; ccg 2046; chaulmoogric acid; chicago sky blue; dihydrogambogic acid; dithranol; epigallocatechin 3,5 digallate; epigallocatechin 3,5 monogallate; evans blue; nf279; protein methyltransferase inhibitor; scintillation; scintillation proximity imaging assay
Journal Title: Combinatorial Chemistry and High Throughput Screening
Volume: 15
Issue: 5
ISSN: 1386-2073
Publisher: Bentham Science Publishers  
Date Published: 2012-06-01
Start Page: 359
End Page: 371
Language: English
DOI: 10.2174/138620712800194468
PROVIDER: scopus
PUBMED: 22256970
PMCID: PMC3553658
DOI/URL:
Notes: --- - "Export Date: 4 June 2012" - "CODEN: CCHSF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Bhavneet Bhinder
    31 Bhinder
  2. Hakim Djaballah
    101 Djaballah
  3. Christophe Antczak
    40 Antczak
  4. Constantin Radu
    28 Radu
  5. Minkui Luo
    70 Luo
  6. David Shum
    54 Shum
  7. Gil Blum
    15 Blum